| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K/A: Financial Statements and Exhibits
On August 10, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal” or the “Company”), completed the acquisition (the “Transaction”) of Kashiv BioSciences, LLC, a Delaware limited liability company (“Kashiv”). The followin... |
| 05 Aug 2025 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, in an advisory vote held at the Annual Meeting on the Say-on-Frequency Proposal, our stockholders expressed their preference for a Say-on-Pay Vote to be conducted every year. Consistent wi... |
| 12 Nov 2024 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ |
| 15 Dec 2023 |
8-K/A: Financial Statements and Exhibits
SECTION 1. OFFICES. Amneal NewCo Inc. (the “Corporation”) shall maintain its registered office in the State of Delaware at 1209 Orange Street, City of Wilmington, County of New Castle, 19801, and its resident agent at such address is the... |
| 17 Apr 2020 | 8-K/A: Financial Statements and Exhibits |
| 20 Feb 2020 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 20 Feb 2020 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 01 Mar 2019 | 8-K/A: Financial Statements and Exhibits |
| 12 Jul 2018 | 8-K/A: Financial Statements and Exhibits |
| 10 May 2018 | 8-K/A: Financial Statements and Exhibits |
Loading...
